sulfisoxazole   Click here for help

GtoPdb Ligand ID: 12700

Synonyms: Gantrisin® | NU-445 | sulfafurazole | sulphafurazole
Approved drug
sulfisoxazole is an approved drug (FDA (1948))
Compound class: Synthetic organic
Comment: Sulfisoxazole (sulfafurazole) is a sulfonamide antibacterial compound [4-5].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 102.16
Molecular weight 267.31
XLogP 0.55
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1=C(NS(=O)(=O)C2=CC=C(C=C2)N)ON=C1C
Isomeric SMILES CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
InChI InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
InChI Key NHUHCSRWZMLRLA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Sulfisoxazole is indicated in the treatment of infections caused by susceptible bacteria, including urinary tract infections, meningococcal meningitis and acute otitis media. Sulfisoxazole has been marketed in a number of jurisdictions, including the US, Canada, Australia, Japan and some European countries. However, there is no information regarding current approval for clinical use of this drug on the US FDA or European Medicines Agency (EMA) websites. Individual national approval agencies may have granted marketing authorisation. Marketed formulations may contain sulfisoxazole acetyl or sulfisoxazole diolamine.
Sulfisoxazole is also used in combination with erythromycin or phenazopyridine.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants [2]. The antibacterial MMOA is competitive inhibition of bacterial dihydropteroate synthase (DHPS) resulting in a block of folate biosynthesis [1].